BioSpace News Archive

Scientific Industries, Inc., a life sciences tool provider, and a developer of digitally simplified bioprocessing products, yesterday reported financial results for the three months ended September 30, 2021.

Promore Pharma AB announced the composition of the Nomination Committee for the Annual General Meeting 2022, which will be held on Tuesday 17 May 2022.

Quanterix Corporation (NASDAQ: QTRX), today announced that its ultra-sensitive Simoa® technology enabled important advances in ongoing clinical trials for the treatment of Alzheimer’s disease.

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, and Bio-Strategy, a leading Australian distributor of equipment and consumables, today announced a distribution agreement to bring Biosero’s Green Button Go® lab automation software and integration solutions to scientists in Australia, New Zealand, and the South Pacific (collectively known as ANZ).

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), today announced that the Company entered into a feasibility study with The Technion Research & Development Foundation Ltd.

New research in the November 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds fewer than one-third of hospitals had immediate availability of a crucial blood cancer medication called all-trans retinoic acid (ATRA).

uLab Systems™, the creator of the uSmile™ clear aligner system and the uDesign® treatment planning software, proudly announced the launch of its new corporate brand identity, redesigned logo, and refreshed website.

Moderna, Inc. today announced an agreement that enables the European Union (EU) and European Economic Area (EEA) countries to donate doses of the Moderna COVID-19 vaccine that they have purchased under the EU Vaccines Strategy to COVAX on an ongoing basis for delivery in 2021.

Genenta Science announced today that it will be presenting updated preliminary Phase I/II clinical data on Temferon at two upcoming scientific congresses.

Quipt Home Medical Corp. is very pleased to announce it has executed a non-binding letter of intent to acquire an arm’s length private respiratory care company in the Midwestern United States reporting unaudited trailing 12-month annual revenues of approximately $13 million, $1.6 million in net income, and positive Adjusted EBITDA.